Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

1. Pusztai, L.
2. Denkert, C.
3. O'Shaughnessy, J.
4. Cortes, J.
5. Dent, R.
6. McArthur, H.
7. Kümmel, S.
8. Bergh, J.
9. Park, Y.H.
10. Hui, R.
11. Harbeck, N.
12. Takahashi, M.
13. Untch, M.
14. Fasching, P.A.
15. Cardoso, F.
16. Zhu, Y.
17. Pan, W.
18. Tryfonidis, K.
19. Schmid, P.